Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ionis Pharmaceuticals

28.40
+0.05000.18%
Post-market: 28.400.00000.00%16:25 EDT
Volume:841.01K
Turnover:23.81M
Market Cap:4.51B
PE:-9.35
High:28.76
Open:28.31
Low:28.04
Close:28.35
Loading ...

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Benzinga
·
04 Jan

Analysts Offer Insights on Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP), Ionis Pharmaceuticals (IONS) and Zura Bio (ZURA)

TIPRANKS
·
25 Dec 2024

Investors Don't See Light At End Of Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Tunnel

Simply Wall St.
·
23 Dec 2024

Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and UnitedHealth (UNH)

TIPRANKS
·
23 Dec 2024

U.S. RESEARCH ROUNDUP-Hershey, Paychex, Revvity

Reuters
·
23 Dec 2024

Intellia Crashes 60% in a Year: How Should You Play the Stock?

Zacks
·
21 Dec 2024

Ionis FDA approval a positive for Arrowhead, says H.C. Wainwright

TIPRANKS
·
20 Dec 2024

Ionis Gets FDA Approval for Rare Disease Drug Tryngolza

Zacks
·
20 Dec 2024

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood

Benzinga
·
20 Dec 2024

BUZZ-Ionis Pharma rises as FDA approves genetic disorder drug

Reuters
·
20 Dec 2024

Ionis Pharmaceuticals reports FDA approval of Tryngolza

TIPRANKS
·
20 Dec 2024

Ionis Pharmaceuticals Says FDA Approved Familial Chylomicronemia Syndrome Drug

MT Newswires Live
·
20 Dec 2024

Ionis Pharmaceuticals trading resumes

TIPRANKS
·
20 Dec 2024

BRIEF-Tryngolza (Olezarsen) Approved In U.S. As First-Ever Treatment For Adults Living With Familial Chylomicronemia Syndrome As An Adjunct To Diet

Reuters
·
20 Dec 2024

Tryngolza™ (Olezarsen) Approved in U.S. as First-Ever Treatment for Adults Living With Familial Chylomicronemia Syndrome as an Adjunct to Diet

THOMSON REUTERS
·
20 Dec 2024

Ionis Pharmaceuticals Inc - Tryngolza to Be Available in U.S. Before Year End

THOMSON REUTERS
·
20 Dec 2024

BRIEF-FDA Approves Ionis Pharmaceuticals' Olezarsen For Familial Chylomicronemia Syndrome- Website

Reuters
·
20 Dec 2024

US FDA approves Ionis Pharma's genetic disorder drug

Reuters
·
20 Dec 2024

FDA Approves Ionis Pharmaceuticals' Olezarsen for Familial Chylomicronemia Syndrome- Website

THOMSON REUTERS
·
20 Dec 2024

Ionis Pharmaceuticals trading halted, news pending

TIPRANKS
·
20 Dec 2024